ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2561

Patient-Centricity: The Keystone to Recruitment and Retention of Research Participants for the Lupus Landmark Study and the Success of the Lupus Nexus

Mary Jo Fekete1, Amonte Davis1, Courtney Canton2, Caroline Donovan3, Carla Menezes4, Derek Bennett5, Brianna Fitzpatrick5, Jamila Jones5, Alison Lee5, Martin Lewis5, Lillian Mendez6, Christine Perkins7, Dayani Tipple8, Ruth Wilson9, S. Sam Lim10, Arezou Khosroshahi11, Alfred Kim12 and Devon Kelly13, 1Lupus Research Alliance, New York, 2Lupus Therapeutics, Charleston, SC, 3Lupus Therapeutics, Charlottesville, VA, 4Lupus Therapeutics, New York, NY, 5Patient Advocate, New York, 6Patient Advocate, Carteret, NJ, 7Patient Advocate, Seattle, Washington, 8AstraZeneca, Wilmington, DE, 9Patient Advocate, Auburn, IN, 10Emory University School of Medicine, Atlanta, GA, 11Emory University, Atlanta, GA, 12Washington University School of Medicine, St. Louis, MO, 13Lupus Research Alliance, New York, NY

Meeting: ACR Convergence 2025

Keywords: longitudinal studies, registry, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (2547–2566) ARP Posters I

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Community-wide access to highly curated, extensive datasets is critical to advance disease understanding and accelerate precision medicine.  To address this unmet need in lupus, the Lupus Research Alliance launched the Lupus Nexus (LNx), an initiative aimed at creating one of the most comprehensive and accessible lupus research datasets ever assembled. Disease heterogeneity, social determinants of health and other factors have made patient recruitment and retention especially challenging in lupus. A patient-centric, collaborative approach to research designs can improve study recruitment, retention and overall robustness of longitudinal datasets.

Methods: From the onset of planning in 2020, individuals living with lupus were engaged to solicit their input on the design and implementation of this unique resource.  Starting with a Patient Engagement Working Group (PEWG) consisting of 9 individuals living with lupus and representing individuals with and without research experience, aspects of the LNx’s architecture (Figure 1) were informed through the qualified patient perspective, including: 

Mapping the patient journey to inform the design of the Lupus Landmark Study
Advising on how data and sample collection methods can be made more convenient for study participants
Advising on outreach strategies to help ensure recruitment targets are met
Providing feedback on educational materials and retention strategies to ensure participant engagement over time

The PEWG evolved into a Patient Advisory Group (PAG) and continues to advise on various areas across the program, now including content and accessibility considerations for a Community Portal, a digital space offering valuable content for those living with lupus (e.g. educational blogs, research highlights) as well as allowing study participants to access study information and results.  As such, the PAG is poised to help transform recruitment and retention methods by employing the use of digital tools amid shifts in technological landscapes.

Results: Including the patient voice as a keystone principle throughout the LNx has led to enhanced research operations while meeting the needs of a broad community. As of 05/12/25, there are 386 participants enrolled in the registry (Table 1), reflecting those disproportionately affected by lupus. By incorporating the voices of those with lupus in developing outreach strategies and design, two years of study operations have resulted in a retention rate of 97%, exceeding early expectations. 

Conclusion: Heterogeneity of disease, social determinants of health and other factors have made study recruitment and retention especially challenging in lupus. The patient-centric approach adopted by the LNx provided valuable inputs to study design, recruitment and sample collection but also inspired patient activation and advanced engagement of patients in research activities. These advocates state that participation empowers them to represent the perspectives of patient sensitivities and creates a sense of community, motivating one another along their journeys. Members of the PEWG and PAG have become organic ambassadors for the program, continuing to inform numerous aspects for this dynamic resource. 

Supporting image 1

Supporting image 2


Disclosures: M. Fekete: None; A. Davis: None; C. Canton: None; C. Donovan: None; C. Menezes: None; D. Bennett: None; B. Fitzpatrick: None; J. Jones: None; A. Lee: None; M. Lewis: None; L. Mendez: None; C. Perkins: None; D. Tipple: AstraZeneca, 3; R. Wilson: None; S. Lim: Accordant, 2, AstraZeneca, 2, Biogen, 5, BMS, 5, Genentech, 2, Gilead, 5, GSK, 2, Novartis, 5, UCB, 5; A. Khosroshahi: Amgen, 1, 2; A. Kim: Abbvie, 2, AstraZeneca, 2, 5, Atara Bio, 2, Bristol Myers Squibb, 5, Cargo Therapeutics, 2, CRISPR Therapeutics, 1, 5, Exagen Diagnostics, 2, 6, Genentech/Roche, 2, GlaxoSmithKline, 2, 6, Hinge Bio, 2, Invivyd, 2, Kypha, Inc., 2, 10, Novartis, 5, Zenas BioPharma, 2; D. Kelly: None.

To cite this abstract in AMA style:

Fekete M, Davis A, Canton C, Donovan C, Menezes C, Bennett D, Fitzpatrick B, Jones J, Lee A, Lewis M, Mendez L, Perkins C, Tipple D, Wilson R, Lim S, Khosroshahi A, Kim A, Kelly D. Patient-Centricity: The Keystone to Recruitment and Retention of Research Participants for the Lupus Landmark Study and the Success of the Lupus Nexus [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/patient-centricity-the-keystone-to-recruitment-and-retention-of-research-participants-for-the-lupus-landmark-study-and-the-success-of-the-lupus-nexus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patient-centricity-the-keystone-to-recruitment-and-retention-of-research-participants-for-the-lupus-landmark-study-and-the-success-of-the-lupus-nexus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology